Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE (PAR: OSE) introduces ‘Cis-Demasking’ technology
Published by Arron Aatkar

OSE has announced the presentation of its new proprietary ‘Cis-Demasking’ bispecific technology called OSE-CYTOMASK, for the design of novel cytokine drugs. OSE-CYTOMASK is a non-cleavable linker technology intended to generate regulated and targeted cytokine therapeutics for the delivery of highly active medicines with improved therapeutic indexes. Management will be presenting further details about OSE-CYTOMASK at a series of upcoming conferences, discussing its preclinical programmes based on an anti-PD1 masked cytokine (IL-2, IL-15), with conditional Cis-Demasking and Cis-Potentiation of tumour-specific T cells expressing PD1 or other immune targe targets.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free